# Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)

> **NCT02047227** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 939 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Pergoveris®
- **DRUG:** GONAL-f®
- **DRUG:** Recombinant human chorionic gonadotrophin (r-hCG)

## Key facts

- **NCT ID:** NCT02047227
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2015-08-31
- **Final completion:** 2015-08-31
- **Target enrollment:** 939 (ACTUAL)
- **Last updated:** 2017-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047227, "Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02047227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*